[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-pelvic-pain-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-pelvic-pain-syndrome":515},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,43,68,96,114,136,160,187,218,250,263,312,334,355,376,397,418,438,467,491],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100054236",false,"NCT06150599","Sacral Neuromodulation for Chronic Pelvic Pain","Sacral Neuromodulation for the Treatment of Chronic Pelvic Pain","SNM_CPP","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Female, aged 22-70\n4. Chronic pelvic pain (= pain below umbilicus) score of 4 or greater on 10-point VAS, present for 6 months or greater (screening patient)\n5. Failed at least 1 or more conservative treatments (e.g. pelvic floor physical therapy, biofeedback, behavioral modification, oral pharmacotherapy, bladder instillations)\n6. No changes to current regimen of medications for their pelvic pain for \\> 4 weeks prior to screening\n7. For females of reproductive potential: use of highly effective contraception (e.g. licensed hormonal or barrier methods), for at least 1 month prior to screening and agreement to use such a method during study participation\n8. Participant agrees not to start any new treatment interventions for CPP prior to Visit 4 (Primary Endpoint)\n\nExclusion Criteria:\n\n1. History of any active pelvic cancer\n2. Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints\n3. Concurrent pain management strategies within the past 3 months that may interfere or mask study intervention (e.g. pelvic floor physical therapy, shockwave therapy, trigger point injections, bladder instillations)\n4. Any psychiatric or personality disorder at the discretion of the study physician. This does not include depression or generalized anxiety disorders that are stable.\n5. Current symptomatic urinary tract infection (UTI) or more than 6 UTIs in past year\n6. Severe or uncontrolled diabetes (A1C \\> 7, documented in the last 3 months) or diabetes with peripheral nerve involvement\n7. Interstitial cystitis diagnosis with Hunner's lesions as this is a severe inflammatory bladder condition that can only be treated with eradication of the lesions or a cystectomy. SNM would be be expected to help for IC with Hunner's lesions\n8. Previously implanted with a sacral neuromodulation device or participated in a sacral neuromodulation trial\n9. Subject with documented history of allergy to titanium, zirconia, polyurethane, epoxy, or silicone\n10. Implantation of spinal cord stimulator and\u002For drug delivery pumps, whether turned on or off\n11. A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception\n12. Current treatment for active malignancy (skin cancers excluded)\n13. Patients with spinal pathology that could confound study results. This may include participants with cauda equina syndrome, spinal stenosis, neurogenic claudication, lumbar radiculopathy, patients with primary complaints of leg pain with numbness and or weakness, patients with a primary pain compliant that is vascular in origin, clinical evidence of progressive neurologic pathology, mechanical instability or other spinal pathology that requires surgical intervention, spine or visceral pain secondary to neoplasm, visceral pain in the upper abdomen rather than the pelvis, current diagnosis of fibromyalgia participants with significant cognitive impairment, participants with a condition currently requiring or likely to require use of diathermy or MRI or history of any other condition that in the opinion of the investigator could put the participant at risk or interfere with study results interpretation. (screening patient).\n14. Participants involved in ongoing litigation and or injury claims or workers compensation claims.\n15. Participation in a current clinical trial or within the preceding 30 days\n\nNote- to preserve the scientific integrity of the study some criteria have been omitted from this posting. All eligibility criteria will be listed at the close of the study.","FEMALE","22 Years","70 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","Sacral neuromodulation (SNM) is a safe, effective, and minimally invasive FDA approved treatment for urinary and fecal incontinence, urinary frequency, urgency, and urinary retention. In this study we are assessing the effectiveness of sacral neuromodulation in women with suffering from chronic pelvic pain (CPP), through a single device implant procedure.",[27],"Chronic Pelvic Pain Syndrome",[29],"Women","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2026-01-27",{"date":38,"type":21},"2028-12-01",{"name":40,"class":41},"Corewell Health East","OTHER",1,{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100641869","NCT07659873","Advancing Online Psychology Tools for Chronic Pain","Advancing Online Psychology Tools for Chronic Pain (ADOPT-CP): Feasibility of a Scalable Digital Psychology Intervention and AI-Powered Support for Patients on the Waitlist for Pain Services","ADOPT-CP","Inclusion Criteria:\n\n1. Must be deemed to have capacity to provide informed consent;\n2. Must sign and date the informed consent form;\n3. Must state willingness to comply with all study procedures;\n4. Must be at least 18 years of age;\n5. Must be referred to TAPMI;\n6. Must have either fibromyalgia or chronic pelvic pain\n7. Must be on the waitlist at TAPMI;\n8. Must have access to a device that can connect to the Internet with access to email.\n\nExclusion Criteria:\n\n1. Currently engaged in psychotherapy or engaged in psychotherapy within the last month at the time of enrolment;\n2. Unable to read, understand, or communicate in English sufficiently to provide informed consent and complete the study procedures and questionnaires;\n3. Has active serious mental illness or psychiatric instability that, in the opinion of the research team, may impair the ability to safely participate in the study or to provide informed consent (e.g., active psychosis, active mania);\n4. Has a visual, auditory, or other functional impairment that would prevent independent access to and use of the digital intervention and study procedures on an internet-enabled device.","ALL","18 Years",{"count":53,"type":21},60,[24],"Chronic pain affects more than 20% of Canadians and is associated with significant impacts on physical function, mental health, and quality of life. Despite efforts to improve access to multidisciplinary pain care through centralized referral systems, many patients continue to experience prolonged wait times before receiving treatment.\n\nThis study evaluates a self-guided digital psychological intervention designed to support chronic pain self-management during the waiting period for specialized pain care. The intervention was developed through a collaboration between the Transitional Pain Service and ManagingLife and aims to improve access to evidence-based psychological support, enhance self-management skills, and reduce pain-related distress among individuals living with chronic pain.",[57,27],"Fibromyalgia","NOT_YET_RECRUITING","2026-06-15",{"date":61,"type":34},"2026-06-22",{"date":63,"type":21},"2026-10",{"date":65,"type":21},"2028-03",{"name":67,"class":41},"Women's College Hospital",{"id":69,"slug":4,"hasResults":10,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":16,"minAge":51,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100528998","NCT06168058","Trial of Ovarian Vein and Pelvic Vein Embolization in Women With Chronic Pelvic Pain and Pelvic Varices","Randomized Controlled, Single-Blinded, Parallel-Group Trial of Ovarian Vein and Pelvic Vein Embolization in Women With Chronic Pelvic Pain and Pelvic Varices (EMBOLIZE) Trial","EMBOLIZE","Inclusion Criteria:\n\n1. Presence of venous origin chronic pelvic pain for greater than 6 months (VAS ≥7 as determined by 4 consecutive weeks of baseline self-assessments) despite non-vascular therapy as delineated by the following criteria:\n\n   * Pain exacerbated by walking, standing or lifting\n   * Symptoms are at least partially alleviated by lying down\n   * Prolonged post-coital ache\n   * Absence of non-venous origin CPP as determined by Gynecology examination\n2. Symptoms-Varices-Pathophysiology Classification18 including of one of the following:\n\n   •S2V2PBGV,R,NT, S2V2PRGV,R,NT , S2V2PLGV,R,NT, with or without S2V2 PBIIV,R,NT, S2V2 PLIIV,R,NT, S2V2 PRIIV,R,NT\n3. CT, TAUS and diagnostic venography (if needed) imaging review for pelvic venous imaging factors\n\n   * Left or right ovarian vein diameter greater than or equal to 6 mm as documented by TAUS or CT\n   * Presence of intrabdominal\u002Fpelvic varices as documented by TAUS or CT (≥1 veins, \\>5 mm diameter)\n   * Presence of venous reflux in ovarian and\u002For internal iliac veins without evidence of hemodynamically significant stenosis\n\nExclusion Criteria:\n\n* Female \\\u003C18 years of age\n* Pregnancy (positive pregnancy test)\n* Female subject who plans to become pregnant during study period\n* Female subject who is actively breastfeeding\n* Patient who is post-menopausal or anovulatory with hormone suppression\n* History of prior hysterectomy\n* Prior ovarian vein embolization or ovarian vein ligation\n* Inability to tolerate endovascular procedure due to acute illness or general health\n* Planned simultaneous treatment with nerve blocks during the duration of the study\n* Laparoscopy or planned surgical intervention during the duration of the study\n* Known allergy to sclerosant, coil, stent or catheter components including nickel allergy\n* Any iliac vein stenosis determined identified by the investigator on pelvic DUS, CT venogram, and\u002For Catheter Venography and deemed significant for exclusion by study patient review committee.\n* Any renal vein stenosis with resultant renal hilar varices\u002Fcollaterals and lumbar collaterals identified by the investigator on pelvic DUS, CT venogram, and\u002For Diagnostic Venography and deemed significant for exclusion by study patient review committee.\n* Presence of isolated extra-pelvic vulvar and\u002For lower extremity varices without intrabdominal pelvic varices. Primary S3 categorization study exclusion.\n* Serious medical conditions that might preclude full participation in the study to the desired endpoint (e.g., uncontrolled diabetes, malignancy, COPD, MI, CHF, etc.)\n* Severe allergy to iodinated or gadolinium-based contrast refractory to steroid premedication\n* Severe renal impairment (on chronic dialysis or estimated GFR \\\u003C30 mL\u002Fmin)\n* Hemoglobin \\\u003C8.0 g\u002FdL, uncorrectable INR \\>3.0 or platelet count \\\u003C75,000\u002Fmicroliter\n* Inability to provide informed consent or to comply with study assessments\n* Post thrombotic IVC, iliac or ovarian vein changes",true,"75 Years",{"count":78,"type":21},40,[24],"The purpose of this study is to see if a randomized controlled trial of ovarian vein and pelvic vein embolization versus venography alone could determine outcomes for women with chronic pelvic pain and pelvic varicose veins.\n\nThe data gathered will assist in addressing changes in quality of life in patients who have ovarian\u002Fpelvic vein embolization versus no embolization.",[27,82,83,84,85],"Pelvic Pain","Pelvic Varices","Pelvic Congestive Syndrome","Pelvic Pain Syndrome","2026-03-11",{"date":88,"type":34},"2026-03-13",{"date":90,"type":34},"2025-08-07",{"date":92,"type":21},"2027-06",{"name":94,"class":41},"Weill Medical College of Cornell University",3,{"id":97,"slug":4,"hasResults":10,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":10,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":42},"100545136","NCT06377969","Prospective Evaluation of Effectiveness and Safety of Closed-Loop Spinal Cord Stimulation in Treating Patients With Chronic Pelvic Pain","Inclusion Criteria:\n\nThe investigators will include all adult patients (18 or older) with pelvic pain more than 6 months that has not responded to conservative medical management\n\nExclusion Criteria:\n\n* Major untreated medical comorbidities (uncontrolled diabetes mellitus, severe obesity, uncontrolled cardiopulmonary disease, etc.)\n* Secondary causes of pelvic pain that can be treated with appropriate medical or surgical interventions\n* Major untreated psychological comorbidities\n* Anatomical challeneges to place spinal cord stimulator\n* Ongoing legal or disability claims",{"count":102,"type":21},10,[24],"Spinal cord stimulation (SCS) is an effective treatment for patients with chronic pelvic pain. The investigators will evaluate how safe and effective closed-loop spinal cord stimulation is in treating these patients; closed-loop spinal cord stimulation is a more novel method in delivering spinal cord stimulation that controls energy output of the device based on real-time feedback on how the device is stimulating the spinal cord.",[27],"2026-03-09",{"date":86,"type":34},{"date":109,"type":34},"2025-06-01",{"date":111,"type":21},"2028-05-31",{"name":113,"class":41},"Stanford University",{"id":115,"slug":4,"hasResults":10,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":10,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":42},"100575883","NCT06778070","National Program to Overcome Pelvic Pain studY (POPPY)","POPPY","Inclusion Criteria:\n\n* Women (individuals reporting female sex assigned at birth who self-identify as women or non-binary) aged 18 years or older\n* Report chronic or recurrent pain in the pelvis (between or below the anterior iliac crests) for at least 6 months\n* Report at least moderate pain intensity based on a screening pain log\n* Report prior clinical evaluation of their pelvic pain by a healthcare professional including at least a superficial pelvic exam\n* Willing to refrain from initiating new clinical treatments that may affect their pain during the study period\n\nExclusion Criteria:\n\n* Report pelvic pain occurring exclusively with menses or exclusively during sexual intercourse (although candidates with at least some pain between menses or intercourse are still eligible)\n* Participation in organized yoga classes or muscle strengthening programs (e.g., Pilates) in the past 4 weeks, or any prior yoga therapy specifically directed at pelvic pain\n* Lacking technical requirements to complete intervention classes by video, including no access to broadband internet or a Zoom-compatible device larger than a smartphone \\[display screen at least 7 inches in diagonal\\] (although the study team may loan devices to participants from underrepresented backgrounds)\n* Currently pregnant (by self-report or screening test), pregnant within the past 12 weeks, or planning pregnancy during the study period\n* Diagnosed with an alternate, reversible cause of pelvic pain that is unlikely to respond to yoga and requires another treatment modality (e.g., current pelvic infection or a gynecologic dermatosis)\n* Surgery or irradiation to the genital or pelvic structures within the past 12 weeks, or anticipating upcoming surgery or irradiation to these structures during the study period\n* Initiation, dose escalation, or weaning of pharmacologic agents that may affect pelvic pain severity in the past 4 weeks, such as analgesics, antidepressants, or anticonvulsants-(however, women on stable doses of these medications for at least 4 weeks will still be eligible)\n* Use of formal psychological therapies specifically for pelvic pain (e.g., systematic desensitization, cognitive therapy, relaxation therapy) within 4 weeks of screening, or plans to engage in these therapies during the study period\n* Unable to walk up a flight of stairs or at least 2 blocks on level ground (i.e., functional capacity \\\u003C 4 METs), or unable to get up from a supine to a standing position without assistance\n* Participation in another interventional study that might interfere with or confound study procedures, or known conflict with multiple upcoming study intervention class dates\n* Inability to understand the informed consent form or fill out questionnaires or complete study interviews\n* Any other serious physical or mental issue that, in the opinion of the investigators, would interfere with study participation (e.g., advanced dementia, uncontrolled substance use or serious mental illness, life expectancy \\\u003C6 months)",{"count":121,"type":21},220,[24],"A randomized, parallel-group, investigator-blinded, comparative effectiveness trial of a fully remote, videoconference-based pelvic floor yoga program versus a physical conditioning program for women with chronic pelvic pain syndrome.",[125,27,126],"Chronic Pelvic Pain Syndrome (CPPS)","Chronic Pelvic Pain","2026-03-04",{"date":129,"type":34},"2026-03-06",{"date":131,"type":34},"2025-05-12",{"date":133,"type":21},"2029-03-15",{"name":135,"class":41},"University of California, San Francisco",{"id":137,"slug":4,"hasResults":10,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":10,"sex":16,"minAge":51,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":42},"100625987","NCT07429773","Identify a Specific Immune Profile in Patients With Chronic Pelvic Pain Resistant to First-line Treatments by Measuring Th1, Th2, Th17, and Treg Cytokines Produced After Non-specific Functional Cell Stimulation - ImmunoCPP","ImmunoCPP","Inclusion Criteria:\n\n1. Aged between 18 and 40;\n2. Under continuous hormone treatment for at least 6 months;\n3. Imaging less than 12 months old: either normal or showing endometriosis and\u002For adenomyosis lesions, excluding any other abnormalities that could explain the PCOS;\n4. Affiliation with the French Social Security system;\n5. Signature of informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women;\n2. Autoimmune disease;\n3. History of cancer within the last 5 years or currently undergoing treatment;\n4. Current infectious syndrome;\n5. Person under guardianship or conservatorship.","40 Years",{"count":144,"type":21},120,[24],"Chronic pelvic pain (CPP) affects more than one in four women. An immune imbalance in the Th1\u002FTh2 balance has been reported in multiple CPP situations, particularly in patients with endometriosis, but with mixed results. The use of a functional immune test, already validated in previous indications and particularly in infertility, could simulate an immune stimulation similar to that of painful attacks.",[148,27],"Endometriosis",[148,27,150],"women","2026-02-17",{"date":153,"type":34},"2026-02-24",{"date":155,"type":21},"2026-04",{"date":157,"type":21},"2028-04",{"name":159,"class":41},"Centre Hospitalier Universitaire de Nice",{"id":161,"slug":4,"hasResults":10,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":10,"sex":50,"minAge":51,"maxAge":18,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":95},"100449064","NCT05127616","EPPIC: Easing Pelvic Pain Interventions Clinical Research Program","A Brief, Transdiagnostic Cognitive Behavioral Treatment for Urological Chronic Pelvic Pain Syndrome: Processes, Predictions, Outcomes","EPPIC","Inclusion Criteria:\n\n* Ages 18-70 years (inclusive)\n* Male or female\n* All genders, races, ethnic groups\n* MD-confirmed diagnosis of IC\u002FBPS or CP\u002FCPPS by study urologist or urogynecologist\n* Pelvic pain including uncomfortable sensations of pressure or discomfort that are not described as outright pain) of at least six months duration\n* Pelvic pain intensity of at least moderate severity (defined as 3 or greater on a 0-10 Numerical Rating Scale and causes life interference weekly and limit(s) participant's life or work-related activities, general activity level, and\u002For enjoyment of life) over the past 3 months.\n* Ability to understand and provide informed consent\n* Either not taking medications or if taking medications willing to refrain from starting new medications until after the initial 2-week pre-treatment baseline period ends unless medically necessary.\n* A minimum 6th grade reading level based on the Wide Range Achievement Test (WRAT 4)\n* Willing to be randomized to either CBT or Support\u002FEducation and to follow the protocol to which s\u002Fhe has been assigned\n* Willing to be contacted for follow up assessments at week 12 and 3, 6 months after treatment ends\n* Willing to attend sessions\n* Able to maintain symptom diaries and complete paper work\n* Access to telephone and computer or smartphone\n* Willing and able to provide adequate information for locator purposes\n\nExclusion Criteria: Urologic-Specific\n\n* Presence of a neurological condition (e.g., MS, Parkinson's disease, paraplegia) affecting the bladder\n* The presence of a symptomatic urethral stricture (males only)\n* History of cystitis caused by tuberculosis or radiation or chemotherapies\n* Participant has been diagnosed and treated for a pelvic-related malignancy (colon, bladder, prostate, ovarian, endometrial, uterine, testicular, penile, cervical, vaginal, or rectal cancer)\n\nExclusion Criteria: General\n\n* Participant has a medical condition(s) whose nature or severity (unstable, life threatening, etc.) would influence adversely the conduct of the clinical trial, confound interpretation of study results, and\u002For compromise volunteer safety and engagement with study demands.\n* Gross cognitive impairment, deafness, blindness, vision problems (severe), hearing problems (severe)\n* Has a major psychiatric disorder which would impede conduct of the clinical study. These clinical disorders would include but are not limited to major depression with a high risk of suicidal behavior (i.e. intent or plan), current or recent (within the past 3 months) history of alcohol or substance abuse\u002Fdependence, a lifetime history of schizophrenia or schizoaffective disorder; or organic mental disorder\n* Current involvement in psychotherapy directed specifically toward relief of urological symptoms\n* Schedule does not permit participation in clinic sessions or home practice including plans to move out of the area, lack of reliable transportation, etc.\n* Characteristics related to inability to complete the study protocol\n* Unable to read or fluently speak English\n* Inability to complete screening visits\n* Inaccessible for interventions and\u002For follow up evaluations",{"count":168,"type":21},240,[24],"The EPPIC (Easing Pelvic Pain Interventions Clinical Research Program) study evaluates an ultra-brief, 4 session cognitive behavioral pain treatment transdiagnostic in design for urologic chronic pain syndrome (UCPPS) with clinical and practical advantages over existing behavioral therapies whose length and focus limits their adoption by clinicians and coverage for mechanistically similar comorbidities. A theoretically informed, practical, empirically grounded approach will systematically unpack CBT's working mechanisms, clarify for whom it works, ease dissemination, appeal to patients, providers, payers, and policy makers in the COVID-19 era favoring low resource intensity treatments, and reduce cost and inefficiencies associated with high intensity therapies whose complexity, length, and scarcity restricts uptake and impact.",[172,173,174,175,176,27,177],"Urologic Chronic Pelvic Pain Syndrome (UCPPS)","Interstitial Cystitis","Bladder Pain Syndrome","Chronic Prostatitis","Chronic Pain","Chronic Overlapping Pain Disorders","2026-01-22",{"date":180,"type":34},"2026-01-26",{"date":182,"type":34},"2022-08-10",{"date":184,"type":21},"2028-07-31",{"name":186,"class":41},"State University of New York at Buffalo",{"id":188,"slug":4,"hasResults":10,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":10,"sex":194,"minAge":142,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":198,"conditions":199,"keywords":205,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":42},"100505998","NCT05868668","Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain","Randomized Controlled Trial of Focused Shockwave, Radial Wave, and Sham Therapy for Erectile Dysfunction and Focused Shockwave and Sham Therapy for Chronic Pelvic Pain Syndrome in Patients With and Without History of Prostate Cancer","Shockwave","Erectile Dysfunction Group (ED) Inclusion Criteria (ED): (all of the following)\n\n1. Cis-gendered heterosexual adult males18 years old\n2. Stable relationship of more than 3 months duration with currently willing sexual partner and desire for penetration.\n3. Mild to moderate organic erectile dysfunction (IIEF-EF score 11-25) in the last 3 months\n4. If ED responsive or partially responsive to current use of PDE5I, participant must be willing to discontinue PDE5I for 4 weeks prior to trial and remain off PDE5I for the duration of the study. Partially responsive ED is defined as inadequate response for desired sexual activity, or poorly maintained erection despite initially good response.\n5. Agreeable to attempt sexual intercourse at least 4 times per month for duration of study without being under the influence of alcohol or recreational drugs\n6. Morning total testosterone level over 300ng\u002FdL\n\nExclusion Criteria (ED):\n\n1. Nerve-injury related ED (\u002Fspinal cord injury, severe lumbosacral disorder (radiculopathy, spinal stenosis) or other neurological disease affecting erectile functions (e.g, multiple sclerosis, alzheimer's disease, parkinsons disease, amyotrophic lateral sclerosis)\n2. Untreated hypogonadism (morning total testosterone \\\u003C300 ng\u002FdL) or on androgen deprivation therapy in the last 12 months\n3. Predominately psychogenic ED based upon expert clinician opinion\n4. Peyronie's disease, palpable plaque or curvature\u002Fpenile anatomic abnormality that affects penetrative intercourse to any degree\n5. History of non-superficial penile surgery (e.g, penile prosthesis, penectomy, plication, grafting)\n6. History of penile injury or trauma (e.g, priapism, penile fracture)\n7. Use of intracavernosal injection for ED within the last year\n8. If diabetic, HbA1c 8% or higher within the past 12 months\n9. Known corporal veno-occlusive dysfunction based on prior Doppler penile ultrasound\n10. Current tobacco smoker, or has smoked in the past year\n11. Poorly controlled hyperlipidemia\n12. Poorly controlled hypertension\n13. Severe cardiac disease or history of myocardial infarction\n14. History of psychiatric disorder including bipolar disorder, current moderate or severe depression\n15. Patients currently using SSRI or psychotropic medication\n16. Severe ED based on IIEF-EF (score 10 or below)\n17. Current acute prostatitis\n\nChronic Pelvic Pain Syndrome Group:\n\nInclusion Criteria (CPPS): (all of the following)\n\n1. Adult males ≥18 years old\n2. Chronic pelvic pain not explained by concurrent urinary tract infections. urine)\n3. Willing to do PFPT\n\nExclusion criteria (CPPS):\n\n1. Nerve-injury related pelvic pain (history of \u002Fspinal cord injury, severe lumbosacral disorder (radiculopathy, spinal stenosis) or other neurological disease affecting pain in the pelvic region(Multiple sclerosis, Alzheimer's, Parkinsons disease)\n2. Acute prostatitis or any acute infection of the pelvic region\n3. History of pelvic trauma","MALE",{"count":196,"type":21},186,[24],"The purpose of this study to perform a randomized, sham controlled analysis of the effectiveness of both fSWT and rWT in the relief of erectile dysfunction and chronic pelvic pain syndrome.",[200,201,202,27,175,203,204],"Erectile Dysfunction Due to Arterial Insufficiency","Erectile Dysfunction","Erectile Dysfunction Due to Arterial Disease","Erectile Dysfunction Following Radical Prostatectomy","Erectile Dysfunction Following Radiation Therapy",[206,207,208],"shockwave","radial wave","pelvic floor physical therapy","2026-01-20",{"date":211,"type":34},"2026-01-21",{"date":213,"type":34},"2023-09-19",{"date":215,"type":21},"2026-06",{"name":217,"class":41},"The Cleveland Clinic",{"id":219,"slug":4,"hasResults":10,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":10,"sex":16,"minAge":224,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":4},"100618211","NCT07328672","Pain Neuroscience Education and Basic Body Awareness Therapy in Women With Chronic Pelvic Pain","Investigation of the Effects of Pain Neuroscience Education and Basic Body Awareness Therapy on Pain, Autonomic Nervous System Responses, and Pelvic Floor Muscle Activity in Women With Chronic Pelvic Pain","Inclusion Criteria:\n\n* Women with any type of chronic pelvic pain, including pelvic floor muscle dysfunction, endometriosis, vulvodynia, genito-pelvic pain\u002Fpenetration disorder, or bladder pain syndrome, with pain persisting for six months or longer.\n\nExclusion Criteria:\n\n* Presence of pelvic infections, inflammatory conditions, or pelvic malignancy.\n* Pregnancy.\n* History of urogynecological surgery within the last six months.\n* Presence of advanced pelvic organ prolapse.\n* Patients currently receiving chemotherapy or radiotherapy.\n* Patients whose primary complaint is not chronic pelvic pain.","20 Years","65 Years",{"count":227,"type":21},45,[24],"This randomized controlled trial aims to investigate the effects of Pain Neuroscience Education and Basic Body Awareness Therapy, when added to standard physiotherapy and rehabilitation, on pain, autonomic nervous system responses, and pelvic floor muscle activity in women with chronic pelvic pain. A total of 45 women diagnosed with chronic pelvic pain will be randomly allocated into three groups: (1) standard physiotherapy and rehabilitation, (2) standard physiotherapy plus Pain Neuroscience Education, and (3) standard physiotherapy plus Basic Body Awareness Therapy. The study will assess pain intensity (algometry, NRS, SF-MPQ), pain catastrophizing, autonomic responses (electrodermal activity), pelvic floor muscle activation (EMG), and related psychological, cognitive, and body awareness parameters. Secondary outcomes will include sexual function, quality of life, and patient satisfaction. The aim is to compare two awareness-based interventions-one primarily mind-to-body (Pain Neuroscience Education) and the other body-to-mind (Basic Body Awareness Therapy)-to determine their relative and complementary effects on pain perception and physiological regulation in women with chronic pelvic pain.",[27,231],"Female",[233,234,235,236,237,238,126,239,240],"Body Awareness","Basic Body Awareness Therapy","Pelvic Floor Muscle Activity","Autonomic Nervous System","Physiotherapy","Rehabilitation","Pelvic Floor Muscles","Pain Neuroscience Education","2025-12-27",{"date":243,"type":34},"2026-01-09",{"date":245,"type":21},"2026-01-15",{"date":247,"type":21},"2026-12-15",{"name":249,"class":41},"Sena Öndeş",{"id":251,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":25,"conditions":254,"keywords":255,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":262,"locationsCount":42},"100527656",{"count":20,"type":21},[24],[27],[29],"2025-12-05",{"date":258,"type":34},"2025-12-11",{"date":260,"type":34},"2025-06-30",{"date":38,"type":21},{"name":40,"class":41},{"id":264,"slug":4,"hasResults":10,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":75,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":270,"phases":4,"briefSummary":271,"conditions":272,"keywords":293,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":42},"100497203","NCT05754190","Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA","INCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week or\n  * Average pain interference score of greater than 3 in the past week or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: greater than 6 months\n* Acute pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week\n\n    ○ or\n  * Average pain interference score of greater than 3 in the past week\n\n    ○ or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: less than 3 months\n  * Pain cause: Due to recent surgery, injury, acute illness, or childbirth (within the past 3 months)\n* Healthy control group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of less than 3 in the past week\n  * Average pain interference score of less than 3 in the past week\n  * Average pain distress score of less than 3 in the past week\n  * No surgery, injury, acute illness, or childbirth (within the past 3 months)\n* In person EEG testing \\[Sub-Study only\\]:\n\n  * Same as in General App Study Above and additionally:\n  * Current diagnosis of Fibromyalgia, Chronic Low Back Pain or Failed Back Surgery Syndrome OR\n  * No current or prior history of chronic pain\n  * If participant has chronic low back pain or failed back surgery syndrome: are they planning to have either a radio-frequency ablation, back surgery, or spinal cord stimulation implant in the next few months\n  * If participant has chronic low back pain or failed back surgery syndrome: have they received insurance approval for the procedure?\n  * Ok with EEC\u002FECG measures\n\nEXCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * recent injury or surgery unrelated to the pain in the past 3 months\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Acute pain group:\n\n  * History of Chronic Pain (Pain lasting for more than 6 months)\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Healthy control group:\n\nHistory of Chronic Pain (Pain lasting for more than 6 months)\n\n* difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n* Not fluent in English (difficulty understanding questions)\n\n  -In person EEG testing \\[Sub-study only\\]: \\[will interfere with EEG data collection safety or quality\\]:\n* Same as in General App Study Above and additionally:\n* Baldness\n* Pregnancy\n* Dreadlocks\n* Left-handedness\n* Use of a wheelchair\n* Heart failure diagnosis\n* Current or prior experience with acute psychosis or mania\n* implanted pacemaker, neurostimulator or any other head or heart implants\n* require a hearing aid to hear properly\n* claustrophobia\n* metal fragments in the body",{"count":269,"type":21},800,"OBSERVATIONAL","This study relies on the use of a smartphone application (SOMA) that the investigators developed for tracking daily mood, pain, and activity status in acute pain, chronic pain, and healthy controls over four months.The primary goal of the study is to use fluctuations in daily self-reported symptoms to identify computational predictors of acute-chronic pain transition, pain recovery, and\u002For chronic pain maintenance or flareups. The general study will include anyone with current acute or chronic pain, while a smaller sub-study will use a subset of patients from the chronic pain group who have been diagnosed with chronic low back pain, failed back surgery syndrome, or fibromyalgia. These sub-study participants will first take part in one in-person EEG testing session while completing simple interoception and reinforcement learning tasks and then begin daily use of the SOMA app. Electrophysiologic and behavioral data from the EEG testing session will be used to determine predictors of treatment response in the sub-study.",[176,273,274,275,276,57,277,278,279,27,280,281,282,283,284,285,286,287,288,289,290,291,292],"Acute Pain","Post Operative Pain","Fibromyalgia, Primary","Fibromyalgia, Secondary","Irritable Bowel Syndrome","Chronic Headache Disorder","Chronic Migraine","Temporomandibular Joint Disorders","Endometriosis-related Pain","Arthritis","Chronic Low-back Pain","Failed Back Surgery Syndrome","Post Herpetic Neuralgia","Neuropathic Pain","Painful Diabetic Neuropathy","Painful Bladder Syndrome","Trauma-related Wound","Trauma, Multiple","Chronic Pain Syndrome","Chronic Shoulder Pain",[294,295,296,297,298,299,300,301,302],"digital health","e-health","smartphone application","chronic pain","acute pain","symptom tracking","experience sampling methodology","ecological momentary assessment","pain self-management","2025-09-16",{"date":305,"type":34},"2025-09-19",{"date":307,"type":34},"2023-06-20",{"date":309,"type":21},"2026-05-30",{"name":311,"class":41},"Brown University",{"id":313,"slug":4,"hasResults":10,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":75,"sex":16,"minAge":51,"maxAge":318,"enrollmentInfo":319,"targetDuration":4,"studyType":22,"phases":320,"briefSummary":321,"conditions":322,"keywords":323,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":4},"100596215","NCT07042555","Efficacy of Cognitive Behavior Therapy for Treatment of Chronic Pelvic Pain in Women","Efficacy of Cognitive Behavior Therapy, Pelvic Floor Therapy and Pharmacotherapy in the Treatment of Chronic Pelvic Pain in Women: A Comparative Study","Inclusion Criteria:\n\nWomen of reproductive age, Women with CPP having no pathological or anatomical causes, Women with Overactive Bladder Syndrome Women with Vulvodynia.\n\nExclusion Criteria:\n\nWomen experiencing per-menopause or menopause, Women with medical, or gynecological or hormonal abnormalities, Women with mental disorders, Women who use substances.","50 Years",{"count":78,"type":21},[24],"The study will employ 4 treatment arms and 1 placebo arm to compare efficacy of CBT, PFT, Pharmacotherapy, Integrated CBT and PFT modalities in the management of chronic pelvic pain in women.",[27],[324],"Chronic Pelvic Pain, Pelvic Pain, Women","2025-06-20",{"date":327,"type":34},"2025-06-29",{"date":329,"type":21},"2025-07-10",{"date":331,"type":21},"2025-12-30",{"name":333,"class":41},"Islamia University of Bahawalpur",{"id":335,"slug":4,"hasResults":10,"nctId":336,"briefTitle":337,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":10,"sex":16,"minAge":51,"maxAge":318,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":344,"conditions":345,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":42},"100528517","NCT06161805","Esketamine as Treatment for Chronic Pain Due to Endometriosis: a RCT Study","EASYlight","Inclusion Criteria:\n\n* Women\n* All pre-menopausal women aged above 18 years\n* Diagnosed with endometriosis (ultrasound, MRI or previous laparoscopic and\u002For diagnostic surgery) according to the #Enzian classification \\[52\\]. This means that endometriosis is present in the following compartments:\n\n  * Rectovaginal space (minimal A1) and\u002For\n  * Sacrouterine ligaments, cardinal ligaments, pelvic sidewall (minimal B1) and\u002For\n  * Rectum (minimal C1) and\u002For\n  * Endometriosis of the intestines, diaphragm and\u002For\n  * Adenomyosis (according to the morphological uterus sonographic assessment (MUSA) or evident adenomyosis on the MRI) \\[53, 54\\] and\u002For\n  * Peritoneal \u002F superficial endometriosis (diagnosed laparoscopically and not treated during surgery).\n* Mild to severe chronic pelvic pain (NRS scale \\>= 6). The 11-point NRS scale ranges from '0' representing no pain to '10' representing the worst pain imaginable.\n* Resistant to current recommended lines of analgesics (paracetamol, NSAIDs)\n* Usage of strong opioids must not have been prescribed or otherwise have been discontinued for more than 1 week.\n* An indication for endometriosis resection surgery or on the waiting list for surgical treatment\n* Ability to understand the patient information letter and to give oral and written informed consent\n* No alteration in the utilization of hormonal therapy ≤1 months prior to inclusion.\n\nExclusion Criteria:\n\n* Pain score \\\u003C6 out of 10 (NRS) for chronic pelvic pain\n* Endometriosis affecting the bladder and ureter\n* Increased intracranial pressure\n* Poorly regulated hypertension, \\>180\u002F100mmHg at rest\n* Patients with thyroid disease\n* Patients with cancer\n* History of psychiatric illness (schizophrenia, psychosis, delirium, manic depression)\n* Serious medical disease (e.g., cardiovascular, renal , pulmonary or liver disease)\n* Severe liver disease\n* Patients with glaucoma\n* Usage of strong opioid medication\n* Usage of xanthine derivatives or ergometrine\n* Unstable angina, heart failure, history of cerebral vascular accident (CVA)\n* Patients suffering from an active infection\n* Patients with epilepsy\n* Patients trying to achieve pregnancy and or patients who are breastfeeding\n* Not being able to answer questionnaires (in Dutch)\n* Mentally incompetent (patients not able to make decisions that are in their best interests, this will be evaluated by their treating physician (e.g. patients with an intellectual disability or mental retardation))\n* Alcohol or drug abuse\n* Patient with a known (es)ketamine allergy\n* Abnormal liver enzyme levels at baseline (ASAT, ALAT, GGT, AF, Bilirubin total)\n\nPatients are allowed to continue the following pain medications: paracetamol, non-steroidal anti-inflammatory drugs as described previously by Sigtermans et al. (Trial NL466 (NTR507))\\* according to their stable use in dose and frequency.\n\n\\*in case of tramadol, amitriptylin, selective serotonin reuptake-inhibitors, gabapentin and pregabalin, the usage may also be continued during this study.",{"count":341,"type":21},56,[343],"PHASE3","The goal of this randomized controlled trial is to investigate the effect of esketamine versus placebo on the NRS score for chronic pelvic pain. Secondary endpoints are to assess pain scores, side-effects, quality of life, depressive symptoms and pain coping.",[148,27],"2025-04-08",{"date":348,"type":34},"2025-04-11",{"date":350,"type":34},"2024-03-01",{"date":352,"type":21},"2026-06-01",{"name":354,"class":41},"Reinier de Graaf Groep",{"id":356,"slug":4,"hasResults":10,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":10,"sex":16,"minAge":361,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":270,"phases":4,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":42},"100496897","NCT05750212","Musculoskeletal and Pelvic Floor Health in Female Chronic Overlapping Pelvic Pain Conditions","Musculoskeletal and Pelvic Floor Health in Female Chronic Overlapping Pelvic Pain Conditions (The MSK-PELVIC Study)","Inclusion Criteria:\n\n* Female sex\n* Age 21 to 80 years\n* Symptoms of CPP as defined by the American College of Obstetrics \\& Gynecology (ACOG) for more than 6 months\n* At least two of seven overlapping CPP diagnosis (i.e., IC\u002FPBS, IBS, Endometriosis, Vulvodynia, PN, FM, PFMP)\n* An average CPP pain score of at least three on a 10 point pain scale\n\nExclusion Criteria:\n\n* Current or history of GI or GU pelvic cancer\n* Current pelvic infection (e.g., a UTI or vaginal infection)\n* Current or imminent planned pregnancy or recent delivery in the last 6 months\n* Abdominal or pelvic surgery in the last 36 months.","21 Years","80 Years",{"count":364,"type":21},208,"The purpose of this study is to learn about nerve function and pelvic muscle function. To do this we will compare the pelvic nerve and muscle function of women with chronic pelvic pain to those who do not have chronic pelvic pain. Understanding the pain may lead to better treatments in the future.",[27],"2025-03-06",{"date":369,"type":34},"2025-03-10",{"date":371,"type":34},"2023-01-24",{"date":373,"type":21},"2025-10-24",{"name":375,"class":41},"Loyola University",{"id":377,"slug":4,"hasResults":10,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":75,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":42},"100565598","NCT06644261","Transvaginal Versus Fluoroscopy-guided Trans Gluteal Pudendal Nerve Block for Pudendal Neuralgia","Transvaginal Versus Fluoroscopy-guided Trans Gluteal Pudendal Nerve Block for Pudendal Neuralgia and Chronic Pelvic Pain: a Prospective, Noninferiority, Randomized Controlled Trial","Inclusion Criteria:\n\n* women \\>18 years\n* English speaking\u002Freading\n* Diagnosis of pudendal neuralgia OR chronic pelvic pain with pain in the distribution of the pudendal nerve for 3 months or longer\n* Minimum pain\u002Fbother score of 4\u002F10\n* Desire for pudendal nerve block\n\nExclusion Criteria:\n\n* Contraindication to pudendal nerve block (examples: skin or vaginal infection, bupivacaine allergy, uncorrected coagulopathy)\n* Pregnant or intending to become pregnant during the study\n* Pudendal nerve block from any route within the last 3 months\n* Major pelvic surgery within the last 3 months (examples: hysterectomy, prolapse repair, midurethral sling)\n* Neurologic disease affecting the perineum (examples: spinal cord injury, multiple sclerosis)",{"count":78,"type":21},[384],"PHASE4","Chronic pain affecting the pelvic and urogenital area is a major clinical problem and can have a profound impact on quality of life and health care costs. Pelvic pain arising from entrapment or neuropathy of the pudendal nerve is known as pudendal neuralgia, which results in chronic perineal pain. This pain syndrome is difficult to diagnose and patients with pudendal neuralgia may present to providers with refractory chronic pelvic pain. Pudendal nerve infiltration or pudendal nerve block (PNB) serves as a diagnostic tool and treatment modality for patients with this condition. To date, there are no published randomized controlled trials comparing imaging-guided PNB to transvaginal finger-guided PNB. While one can assume that image-guided nerve blocks will provide better accuracy for injection and potentially better efficacy in pain relief as a result, no published data exists comparing the outcomes and efficacy between modalities.\n\nThe purpose of this prospective, non-inferiority, randomized controlled trial is to compare the efficacy of pain relief from bilateral transvaginal finger-guided pudendal nerve block versus bilateral fluoroscopy-guided trans gluteal pudendal nerve block for patients with pudendal neuralgia.",[387,27],"Pudendal Neuralgia","2024-12-13",{"date":390,"type":34},"2024-12-18",{"date":392,"type":34},"2024-06-27",{"date":394,"type":21},"2029-07-01",{"name":396,"class":41},"University of Louisville",{"id":398,"slug":4,"hasResults":10,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":10,"sex":16,"minAge":51,"maxAge":403,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":42},"100555024","NCT06506708","Effect of Massage and Hydrotherapy to Improve Well-being and Pain Perception in Endometriosis Patients","Effect of Massage and Hydrotherapy to Improve Well-being and Pain Perception in Women With Endometriosis Unresponsive to Conventional Treatment","Inclusion Criteria:\n\n* Pelvic pain during the last 6 months more or equal to 4 in a NRS scale.\n* Diagnosed with endometriosis (through surgery, magnetic resonance imaging or ultrasound imaging)\n* Premenopausal status\n* Be able to walk without assistance and to read and write enough\n* Be capable and willing to provide consent\n\nExclusion Criteria:\n\n* Acute or terminal illness\n* A recent fracture in any upper or lower extremity (\\\u003C3 months), disc herniation and any chronic disease or orthopaedic issues that would interfere with her ability to participate in this intervention program\n* Express unwillingness to complete the study requirements\n* Be involved in other rehabilitation program","55 Years",{"count":405,"type":21},44,[24],"The objective is to analyze the short-term effect of a comprehensive HAMMAM experience combining therapeutic hydrotherapy, aromatherapy, music therapy, and Swedish massage on objective parameters and patient-reported outcomes related to well-being generation and pain reduction in women with endometriosis-related chronic pelvic pain.",[148,27],"2024-07-16",{"date":411,"type":34},"2024-07-17",{"date":413,"type":34},"2023-05-01",{"date":415,"type":21},"2024-07-31",{"name":417,"class":41},"Universidad de Granada",{"id":419,"slug":4,"hasResults":10,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":10,"sex":16,"minAge":51,"maxAge":424,"enrollmentInfo":425,"targetDuration":4,"studyType":22,"phases":426,"briefSummary":427,"conditions":428,"keywords":429,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":4},"100550339","NCT06445790","Efficacy of Cognitive Behavior Therapy in the Treatment of Chronic Pelvic Pain in Women","Efficacy of Cognitive Behavior Therapy in the Treatment of Chronic Pelvic Pain in Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Women of reproductive age.\n2. Women with Chronic Pelvic Pain having no pathological or anatomical causes.\n3. Women with Overactive Bladder Syndrome.\n4. Women with Vulvodynia. -\n\nExclusion Criteria:\n\n1. Women experiencing perimenopause or menopause.\n2. Women with medical, or gynecological or hormonal abnormalities.\n3. Women with mental disorders.\n4. Women who use substances. -","45 Years",{"count":53,"type":21},[24],"This will be the pilot study trial. The target population will be 30 individuals with Chronic Pelvic Pain (CCP). There will be 02 groups, Experimental Group and Control Group. The primary outcome measure will be Impact of Female Chronic Pelvic Pain Questionnaire (IF-CPPQ). The experimental group will receive CBT spread over 12 sessions.",[27],[324],"2024-06-05",{"date":432,"type":34},"2024-06-06",{"date":434,"type":21},"2024-06-20",{"date":436,"type":21},"2024-10-20",{"name":333,"class":41},{"id":439,"slug":4,"hasResults":10,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":10,"sex":194,"minAge":51,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":22,"phases":445,"briefSummary":446,"conditions":447,"keywords":450,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":42},"100524926","NCT06115083","Effects of Pelvic Floor Training in Male Chronic Pelvic Pain, Correlation Between Subjective and Objective Outcomes","Long Term Effects of Pelvic Floor Re-education in Men With Chronic Pelvic Pain, Using Bio-feedback and Home Training - Subjective Outcomes in Correlation to Objective Measurements of the Lower Urinary Tract and Pelvic Floor","Inclusion Criteria:\n\n* Men over the age of 18, residents in Sweden, diagnosed with Chronic Primary Pelvic Pain Syndrome (CPPPS) according to the International Statistical Classification of Diseases and Related Health Problems (ICD-10) (N41.1 (chronic prostatitis), N41.9 (Inflammatory disease of prostate, unspecified), N50.8F (Chronic Pelvic Pain Syndrome in men)\n\nExclusion Criteria:\n\n* Cancer in the abdomen or pelvic organs (current or previous)\n* Congenital anomalies affecting the pelvic region (Bladder exstrophy, Myelomeningocele etc.)\n* Transsexual male, (i.e. at birth biologically female)\n* Diseases affecting the nerve function to the pelvic and\u002For lower extremities, other disease or ongoing treatment that could have an impact on the outcome of the study.\n* Incapability to participate in testing or follow training instructions due to mental incapacity, language difficulties etc.",{"count":78,"type":21},[24],"The goal of this randomized controlled study is to establish the long-term effect of pelvic floor re-education using biofeedback and home training for men with chronic pelvic pain. The main questions it aims to answer are if pelvic floor re-education using bio-feedback and home training will give a long-lasting improvement in symptoms, assessed with a validated symptom score (the National Institute of Health - Chronic Prostatitis Symptom Index) and if an improvement in symptoms can be correlated to objective measurements of pelvic floor function. Participants will be asked to do pelvic floor exercises daily during six months with additional sessions of bio-feedback training. The control group will have no changes in their on-going treatment for their chronic pelvic pain and will be offered to enter the treatment group after six months.",[27,448,175,449],"Chronic Prostatitis With Chronic Pelvic Pain Syndrome","Pelvic Floor; Relaxation",[451,452,453,454,455,237,456],"Chronic pelvic pain syndrome","Chronic prostatitis with chronic pelvic pain syndrome","Chronic prostatitis","Pelvic floor muscles","Urodynamics","Bio-feedback","2024-04-12",{"date":459,"type":34},"2024-04-16",{"date":461,"type":34},"2023-12-01",{"date":463,"type":21},"2026-12",{"name":465,"class":466},"Region Stockholm","OTHER_GOV",{"id":468,"slug":4,"hasResults":10,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":10,"sex":16,"minAge":51,"maxAge":318,"enrollmentInfo":473,"targetDuration":4,"studyType":22,"phases":475,"briefSummary":476,"conditions":477,"keywords":479,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":42},"100543830","NCT06360965","Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain","A Randomized Controlled Trial on the Clinical Efficacy and Safety of Warm Meridians and Relieve Pain Plaster in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain (Cold Dampness Stasis Type).","Inclusion Criteria:\n\n1. Meets the diagnostic criteria of traditional Chinese and Western medicine for sequelae of pelvic inflammatory disease and chronic pelvic pain;\n2. Transvaginal ultrasound examination shows thickening of the fallopian tube wall and fluid accumulation in the lumen, which may be accompanied by pelvic free fluid or fallopian tube ovarian masses;\n3. The age range is 18-50 years old, married or with a history of sexual activity;\n4. Those with a menstrual cycle of 21-35 days;\n5. 4 points ≤ Pain Visual Analog Scale (VAS) \\\u003C 7 points;\n6. Those who have signed an informed consent form and are willing to receive treatment.\n\nExclusion Criteria:\n\n1. Female patients who have fertility requirements during pregnancy, lactation, or in the short term;\n2. Patients with gynecological diseases such as organic lesions of the reproductive system or gynecological acute abdomen;\n3. Chronic pelvic pain caused by gynecological tumors, endometriosis, pelvic congestion syndrome, uterine fibroids, tuberculous pelvic inflammatory disease, and other diseases confirmed through examination;\n4. Those with severe diseases such as cardiovascular, cerebrovascular, liver and kidney function, and digestive system;\n5. Individuals with mental abnormalities and psychological disorders;\n6. Individuals with allergic constitution or known allergies to the drugs and their components used in this experiment;\n7. Patients currently participating in clinical trials of other drugs;\n8. Other methods of treatment have already been or are currently being carried out, which may affect the indicators observed in this study.",{"count":474,"type":21},102,[24],"Chronic Pelvic Pain is one of the common gynecological symptoms, characterized by persistent and non periodic pain in the pelvic cavity and surrounding tissues. It is often seen as a sequelae of pelvic inflammatory diseases caused by the failure to receive timely and correct treatment. This study compares the effectiveness of warm meridians and relieve pain plaster in relieving the sequelae of pelvic inflammatory disease and chronic pelvic pain symptoms, and evaluates the safety of improved patches and traditional patches, further promoting it to community grassroots hospitals.",[478,27],"Pelvic Inflammatory Disease",[478,27,480,481],"acupoint application","cold dampness stasis type","2024-04-06",{"date":484,"type":34},"2024-04-11",{"date":486,"type":34},"2024-01-01",{"date":488,"type":21},"2026-12-31",{"name":490,"class":41},"Beijing Hospital of Integrated Traditional Chinese and Western Medicine",{"id":492,"slug":4,"hasResults":10,"nctId":493,"briefTitle":494,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":10,"sex":16,"minAge":51,"maxAge":403,"enrollmentInfo":496,"targetDuration":4,"studyType":22,"phases":498,"briefSummary":499,"conditions":500,"keywords":501,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":42},"100532172","NCT06209346","Multimodal Physiotherapy Based on Tele-rehabilitation in Chronic Pelvic Pain Associated With Endometriosis","Inclusion Criteria:\n\n* Women with a medical diagnosis of endometriosis.\n* Age equal to or older than 18 years and up to 55 years.\n* Who are or have received medical and\u002For surgical treatment and with controlled disease.\n* Persistent pelvic pain for at least 3 months.\n* Pain greater than 4 on the EVN.\n* No cognitive limitation to understand the information sheet, instructions and freely sign the informed consent\n* Have any electronic device available (tablet, computer, cell phone).\n* Have a current email address.\n* Have a valid e-mail address.\n\nExclusion Criteria:\n\n* Peri- and postmenopausal women.\n* Women pregnant or desiring gestation during the study.\n* Women with a history of gynecologic cancer and\u002For undergoing any systemic and\u002For localized oncologic treatment in the pelviperineal region\n* Women with a diagnosis of chronic fatigue or fibromyalgia▪.\n* Women concomitantly participating in another intervention study.\n* Women undergoing surgery during the study.",{"count":497,"type":21},66,[24],"* Objective: To determine if the tele-rehabilitation program for chronic pelvic pain associated with endometriosis composed of pain education, therapeutic exercise and respiratory control decreases pain according to the Visual Numerical Scale (EVN), catastrophizing with the Pain Catastrophizing Scale (PCS), kinesiophobia with the Tampa Scale of Kinesiophobia (TSK), improves sexual function according to the Female Sexual Function Index (FSFI) and QoL compared to the Control Group with the Health Status Questionnaire (SF-12).\n* Follow-up: four evaluated questionnaires: preintervention; postintervention, 3 months postintervention, 6 months postintervention\n* Participants: 66 women diagnosed with endometriosis with chronic pelvic pain in different Spanish endometriosis associations.\n* Randomization: women will be randomly assigned to two groups using the EpiData 3.1 software\n* Interventions: Experimental Group: therapeutic exercise + conscious breathing (16 sessions) and pain education (4 sessions) through the TRAK platform.\n\nControl Group: They will receive informative material in weeks 1, 3, 5 and 7 about their pathology and with recommendations for them to achieve healthy lifestyle habits that do not further damage their disease.",[148,27],[502,503,504,505],"endometriosis","chronic pelvic pain","physical therapy","pain education","2024-01-07",{"date":508,"type":34},"2024-01-17",{"date":510,"type":34},"2023-11-27",{"date":512,"type":21},"2027-01-17",{"name":514,"class":41},"University of Alcala",""]